Aquatic Capital Management LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Aquatic Capital Management LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 201.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 235,414 shares of the biopharmaceutical company’s stock after acquiring an additional 157,214 shares during the quarter. Aquatic Capital Management LLC owned approximately 0.08% of Amicus Therapeutics worth $2,218,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. lifted its stake in Amicus Therapeutics by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 1,280 shares during the last quarter. Xponance Inc. lifted its stake in Amicus Therapeutics by 11.9% in the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 2,249 shares during the last quarter. Covestor Ltd lifted its stake in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 2,312 shares during the last quarter. KBC Group NV lifted its stake in Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 3,120 shares during the last quarter. Finally, Swiss National Bank lifted its stake in Amicus Therapeutics by 0.7% in the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company’s stock worth $4,121,000 after acquiring an additional 3,200 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Amicus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $7.39 on Tuesday. Amicus Therapeutics, Inc. has a fifty-two week low of $6.20 and a fifty-two week high of $12.65. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -41.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. The firm has a 50-day simple moving average of $8.11 and a 200-day simple moving average of $9.37. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.